This Article Full Text Full Text (PDF) All Versions of this Article: 106/14/1794    most recent 01.CIR.0000031735.86021.79v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Abraham, M.R. Articles by Johnson, B. D. Search for Related Content PubMed PubMed Citation Articles by Abraham, M.R. Articles by Johnson, B. D. Related Collections Other heart failure Exercise/exercise testing/rehabilitation

(Circulation. 2002;106:1794.)
© 2002 American Heart Association, Inc.

Clinical Investigation and Reports

Angiotensin-Converting Enzyme Genotype Modulates Pulmonary Function and Exercise Capacity in Treated Patients With Congestive Stable Heart Failure

M.Roselle Abraham, MD; Lyle J. Olson, MD; Michael J. Joyner, MD; Stephen T. Turner, MD; Ken C. Beck, PhD; Bruce D. Johnson, PhD

From the Divisions of Cardiovascular (M.R.A., L.J.O., B.D.J.) and Thoracic (K.C.B.) Diseases and Hypertension (S.T.T.), and the Department of Anesthesiology (M.J.J.), Mayo Clinic and Foundation, Rochester, Minn.

Correspondence to Bruce D. Johnson, PhD, Division of Cardiovascular Diseases, Mayo Clinic, 200 First St SW, Rochester, MN 55905. E-mail johnson.bruce{at}mayo.edu

Background— The gene encoding ACE exhibits an insertion/deletion polymorphism resulting in 3 genotypes (DD, ID, and II), which affects serum and tissue ACE activity as well as other vasoactive substances. Pulmonary function is frequently abnormal in patients with congestive heart failure (CHF), the mechanism of which has not been completely characterized. ACE inhibition has been shown to improve diffusion across the alveolar-capillary membrane and to improve exercise capacity and gas exchange in CHF. The aim of the current study was to determine if ACE genotype is associated with altered pulmonary function and exercise intolerance in patients with treated CHF.

Methods and Results— Fifty-seven patients (stratified according to ACE genotype as17 DD, 28 ID, 12 II) with ischemic and dilated cardiomyopathy, left ventricular ejection fraction (LVEF) <35%, and <10 pack-years of smoking history were studied. All patients were receiving standard therapy for left ventricular systolic dysfunction. Pulmonary function, LVEF, serum ACE, plasma angiotensin II, atrial natriuretic peptide, and brain natriuretic peptide were measured at baseline. Peak O₂ and gas exchange measurements were assessed with graded exercise. Resting LVEF was similar among the genotype groups (25% to 28%), and no differences were observed in diastolic function or pulmonary artery pressures (P>0.05). Mean peak O₂ and forced vital capacity (% Pred) were significantly reduced (P<0.05), whereas mean serum ACE activity and plasma angiotensin II concentration were highest in DD homozygotes. Subjects homozygous for the D-allele also demonstrated higher mean ventilatory equivalents for carbon dioxide (E/CO₂) during exercise (P<0.05).

Conclusions— ACE DD genotype is associated with decreased exercise tolerance in CHF, possibly mediated by altered pulmonary function. Pharmacological strategies effecting more complete inhibition of serum and tissue ACE and/or potentiation of bradykinin may improve exercise capacity in patients with CHF and ACE DD genotype.

Key Words: heart failure • angiotensin • renin • lung

This article has been cited by other articles:

				R. Arena, J. Myers, and M. Guazzi The Clinical Significance of Aerobic Exercise Testing and Prescription: From Apparently Healthy to Confirmed Cardiovascular Disease American Journal of Lifestyle Medicine, November 1, 2008; 2(6): 519 - 536. [Abstract] [PDF]

				P. M. Kirshbom, W. T. Mahle, R. W. Joyner, T. Leong, M. Wilson, B. E. Kogon, K. R. Kanter, and M. M. Bouzyk The endothelin-1 G5665T polymorphism impacts transplant-free survival for single ventricle patients J. Thorac. Cardiovasc. Surg., July 1, 2008; 136(1): 117 - 122. [Abstract] [Full Text] [PDF]

				A. M. Feldman The emerging role of pharmacogenomics in the treatment of patients with heart failure Ann. Thorac. Surg., December 1, 2003; 76(6): S2246 - 2253. [Full Text] [PDF]

				M. Guazzi Alveolar-Capillary Membrane Dysfunction in Heart Failure: Evidence of a Pathophysiologic Role Chest, September 1, 2003; 124(3): 1090 - 1102. [Abstract] [Full Text] [PDF]

				R Forth and H Montgomery ACE in COPD: a therapeutic target? Thorax, July 1, 2003; 58(7): 556 - 558. [Full Text]

				J.-F. Jasmin, A. Calderone, T.-K. Leung, L. Villeneuve, and J. Dupuis Lung structural remodeling and pulmonary hypertension after myocardial infarction: complete reversal with irbesartan Cardiovasc Res, June 1, 2003; 58(3): 621 - 631. [Abstract] [Full Text] [PDF]